{"created":"2023-06-19T09:40:21.333926+00:00","id":513,"links":{},"metadata":{"_buckets":{"deposit":"c3f6817b-c575-4027-b45d-1c5045bf54bc"},"_deposit":{"created_by":18,"id":"513","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"513"},"status":"published"},"_oai":{"id":"oai:yasuda-u.repo.nii.ac.jp:00000513","sets":["7:58"]},"author_link":["84","750"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-02-28","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"48","bibliographicPageEnd":"360","bibliographicPageStart":"351","bibliographic_titles":[{"bibliographic_title":"安田女子大学紀要","bibliographic_titleLang":"ja"},{"bibliographic_title":"Journal of Yasuda Women's University","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":" 　甲状腺未分化癌は今日なお極めて予後不良で、１年生存を得ることはほとんどない。たとえ周囲臓器を含む拡大手術を施行しても肺などの多発遠隔転移によってきわめて短い月数しか延命できないことがほとんどであり、従来の化学療法や放射線治療はほとんど無効である。1978年以降の自験例を振り返ってみても、改めてその治療結果の厳しさが示された。\n 　近年本邦でも分子標的薬であるレンバチニブが甲状腺未分化癌に使用できることになったので、最近３年間のレンバチニブによる治療例報告を渉猟し、その臨床効果を検討した。これまでにない奏功は示されることが多いが、有害事象のために減量あるいは休薬するとたちまち腫瘍の増悪をきたすことが示されていた。\n 　難治性甲状腺癌症例に対して分子標的治療薬は従来にない治療効果、延命効果が期待されている。極めて致死的な甲状腺未分化癌に対しては更なる有効で予後を改善する薬剤の開発、治療法の開発が望まれる。","subitem_description_type":"Abstract"}]},"item_10002_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24613/00000492","subitem_identifier_reg_type":"JaLC"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"安田女子大学","subitem_publisher_language":"ja"}]},"item_10002_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00242368","subitem_source_identifier_type":"NCID"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0289-6494","subitem_source_identifier_type":"PISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"宮原, 裕","creatorNameLang":"ja"},{"creatorName":"ミヤハラ, ヒロシ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyahara, Hiroshi","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-03-19"}],"displaytype":"detail","filename":"02896494048036.pdf","filesize":[{"value":"1.4 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"02896494048036.pdf","url":"https://yasuda-u.repo.nii.ac.jp/record/513/files/02896494048036.pdf"},"version_id":"cd37e173-6cb9-4ddd-b901-6866df17ad45"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"難治性甲状腺癌","subitem_subject_scheme":"Other"},{"subitem_subject":"甲状腺未分化癌","subitem_subject_scheme":"Other"},{"subitem_subject":"致死的","subitem_subject_scheme":"Other"},{"subitem_subject":"分子標的治療薬","subitem_subject_scheme":"Other"},{"subitem_subject":"レンバチニブ","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"難治性甲状腺癌に対して分子標的治療薬は予後を改善するか －とくに未分化癌を中心に－","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"難治性甲状腺癌に対して分子標的治療薬は予後を改善するか －とくに未分化癌を中心に－","subitem_title_language":"ja"},{"subitem_title":"Does Molecular-Targeted Therapeutics Improve Convalescence for Intractable Thyroid Cancer, Specifically Anaplastic Thyroid Cancer ?","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"18","path":["58"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2020-03-19"},"publish_date":"2020-03-19","publish_status":"0","recid":"513","relation_version_is_last":true,"title":["難治性甲状腺癌に対して分子標的治療薬は予後を改善するか －とくに未分化癌を中心に－"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2024-01-31T04:04:21.400750+00:00"}